DOI 10.1016/j.amjsurg.2025.116389
Evaluating the efficacy and safety of low-molecular weight heparin as a chemoprophylactic agent in stable traumatic brain injury.
Аннотация
BACKGROUND
There is a lack of high-quality evidence regarding the most appropriate pharmacologic venous thromboembolism chemoprophylaxis (VTEp) agent in traumatic brain injury (TBI). Low-Molecular Weight Heparin (LMWH) is presumed to reduce VTE events; however, concerns of worsening intracranial hemorrhage (ICH) persist. The aim of the present study is to compare the efficacy and safety of LWMH versus Unfractionated Heparin (UFH) in patients with non-operative TBI.
METHODS
We performed a single-center retrospective review of all adult TBI patients (age ≥18years) admitted to a Level I trauma center (2015-2022). Exclusion criteria included neurosurgical intervention prior to VTEp, absence of VTEp, worsened ICH prior to VTEp initiation, and death or discharge within 48 h of admission. The study population was stratified into those who received LMWH versus UFH as VTEp. The primary outcome of interest was VTE events. Secondary outcomes included worsening ICH, transfusion requirements, and in-hospital mortality.
RESULTS
A total of 2176 patients met inclusion criteria (median age 62 years and 64 % male) of whom 68 % received UFH while 32 % received LMWH. Overall, there was no significant difference in demographics, injury characteristics, and time to VTEp initiation; however, compared to patients who received UFH, those who received LMWH were younger (51 vs 68 years p < 0.001) and less likely to present with a subdural hematoma (59 % vs 65 % p = 0.02). The LMWH cohort had a lower rate of VTE events (1.4 % vs 3.0 %; p = 0.03) and in-hospital mortality (1.4 % vs 3.9 %; p < 0.01). No significant differences in worsening ICH (2.8 % vs 3.3 %; p = 0.2) or transfusion requirements (7.7 % vs 8.2 %; p = 0.6) were detected. After controlling for age, ISS, BMI, and presence of SDH, LMWH was associated with lower odds of VTE events (AOR: 0.47, 95 %CI: 0.30-0.86) but not mortality (AOR: 0.65, 95%CI: 0.47-1.22).
CONCLUSION
Compared to UFH, LMWH is a safe and effective chemoprophylactic agent in patients with non-operative stable TBI.
LEVEL OF EVIDENCE: Level III, Therapeutic/Care Management.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.